Trials / Completed
CompletedNCT04393233
Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- University Hospital, Brest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.
Conditions
Timeline
- Start date
- 2020-04-23
- Primary completion
- 2020-08-23
- Completion
- 2020-08-23
- First posted
- 2020-05-19
- Last updated
- 2024-08-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04393233. Inclusion in this directory is not an endorsement.